Table 1.
Summary of nabilone studies.
| First Author, Year | Country | Study Drug | Posology | Duration | Enrolled Patients | Patients Who Have Completed the Trial | Mean Age [yrs (SD)] | Sex [M/F (N)] | Outcomes | Reported Adverse Events |
|---|---|---|---|---|---|---|---|---|---|---|
| Hermann, 2019 | Canada | nabilone | 1–2 mg once a day | 14 weeks | 39 | 33 | placebo & active: 87 (10) | 30/9 | Efficacy and safety of nabilone for agitation with moderate to severe Alzheimer’s | Sedation (including lethargy, treatment limiting sedation, significant increase in NPS, myocardial infarction, bradycardia, rash, dizziness, lethargy |
| Kalliomäki 2012 | UK | nabilone | 1–3 mg | 7 weeks & 5 days | 30 | 24 | placebo & active: 29.3 (no data) | 30/0 | Effect of nabilone on capsaicin-induced pain and hyperalgesia and on other CNS biomarkers | Somnolence, Postural dizziness, Tachycardia, Bradycardia, Dizziness, Headache, Fatigue, Dry mouth |
| Pooyania, 2010 | Canada | nabilone | 0.5 mg once or bid | 10 weeks | 12 | 11 | placebo & active: 42.36 (no data) | 11/0 | Alleviation of spasticity in patients with spinal cord injury (SCI) | Ataxia, Drowsiness, Vertigo (mild), Lack of motivation, Headache, Asthenia, Dry mouth |
| Redmond, 2008 | Canada | nabilone | 0.5–1 mg | 3 visits with washout periods of at least one week | 20 | 17 | placebo & active: male: 22.5 (1.5) female: 23.2 (2.8) | 7/10 | Analgesic and antihyperalgesic properties of nabilone | Mild sedation, Euphoria, Feeling cold, Nausea, Dizziness, Headache, Increased appetite, Dry mouth |
| Skrabek, 2008 | Canada | nabilone | 0.5–1 mg bid | 4 weeks | 40 | 33 | placebo: 50.11 (5.96) active: 47.6 (9.13) | 37/3 | Benefit of nabilone in pain management and QoL improvement in patients with fibromyalgia | Euphoria, Depression, Psychological high, Dissociation, Nightmares, Decreased concentration, Ataxia, Confusion, Hallucination, Orthostatic hypotension, Tachycardia, Sensory disturbance, Drowsiness, Lightheaded, Vertigo, Headache, Dysphoria, Anorexia, Dry mouth |
| Wissel, 2006 | Austria/Germany | nabilone | 0.5 mg once or tid | 9 weeks | 13 | 11 | placebo & active: 44.85 (13.82) | 4/9 | Efficacy and safety of low dose nabilone in spasticity related pain | Dysphagia (slight), Drowsiness, Weakness in lower limbs (slight) |
F: female, M: male, ND: no data, yrs: years, bid: twice a day, tid: three times daily.